{"url_path":"/sec/vtvt/8-k/2026-05-13/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1641489/0001193125-26-221971-index.html","accession_number":"0001193125-26-221971","cik":"0001641489","ticker":"VTVT","issuer_name":"vTv Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1641489/0001193125-26-221971-index.html","primary_entity_key":"0001641489","primary_entity_name":"vTv Therapeutics Inc."},"word_count":118,"has_tables":true,"body_markdown":"Item 8.01.\n\nOther Events.\n\nOn May 13, 2026, vTv Therapeutics Inc. (the “Company”) filed a prospectus supplement with the SEC to increase the number of shares of Class A common stock offered under its previously-announced at-the-market sales program (the “ATM Program”) to the full amount provided for under the ATM program. In connection with the ATM Program, the Company is filing a legal opinion of Dechert LLP regarding the legality of the Class A common stock issuable under the ATM Program, which legal opinion is attached as Exhibit 5.1 to this Current Report on Form 8-K, in order to incorporate such legal opinion by reference into the Company’s effective shelf Registration Statement on Form S-3 regarding such shares."}